Biomanufacturing Excellence Act of 2025
- Sponsor
- Sen. Coons, Christopher A. [D-DE]
- Committees
- Commerce, Science, and Transportation Committee (primary)
- Last action
- Nov 18, 2025
Bottom line
This bill aims to bolster U.S. leadership in biotechnology and biopharmaceutical manufacturing by creating a dedicated center for innovation, workforce development, and supply chain resilience.
What it actually does
This bill establishes a National Biopharmaceutical Manufacturing Center of Excellence within the National Institute of Standards and Technology (NIST) to advance the science of biopharmaceutical manufacturing, support good manufacturing practices, and develop workforce training. It authorizes $120,000,000 for fiscal year 2026 to fund the center's establishment, facility construction, research, and training programs.
Proponents argue
Supporters argue that investing in biomanufacturing will reduce dependency on foreign supply chains, strengthen national and health security, and create high-skilled jobs. They emphasize the need for flexible and affordable infrastructure to scale innovative products from lab to commercial production, ensuring the U.S. remains competitive in this critical sector.
Opponents contend
No explicit opposition is identified within the bill's findings or sense of Congress. Potential criticisms might revolve around the cost, the effectiveness of a single center versus a more distributed approach, or concerns about the extent of government involvement in private industry, but these are not articulated in the provided text.
The bill is relatively short and clearly structured, making it accessible for a reader to understand its core proposals within a reasonable timeframe.
Section 3, new Section 36(a) of the NIST Act
Establishment of the National Biopharmaceutical Manufacturing Center of Excellence
This provision directs the Director of the National Institute of Standards and Technology (NIST) to award a grant or enter an agreement with an eligible entity to establish and operate a new center. The center's main goals include advancing biopharmaceutical manufacturing science, supporting good manufacturing practices, developing workforce training, and fostering collaboration among various institutions to deploy innovative manufacturing infrastructure.
Supporters argue
Supporters argue this center is crucial for the U.S. to maintain global leadership in biotechnology, reduce reliance on foreign supply chains, and accelerate the development of life-saving medicines and other bio-products. They believe it will bridge the gap between lab innovation and commercial-scale production.
Critics contend
No specific opposition is typically raised against the establishment of centers of excellence for critical technologies, though some might question the specific funding mechanism or potential for bureaucratic inefficiencies.
Tradeoffs
The primary tension is balancing the need for rapid innovation and commercialization with ensuring rigorous quality control and regulatory compliance in biopharmaceutical manufacturing. Another tension is ensuring equitable access to the center's resources for diverse entities.
Section 3, new Section 36(a)(3) and 36(b) of the NIST Act
Funding Authorization and Competitive Application Process
This section authorizes $120,000,000 for fiscal year 2026 to fund the Center of Excellence, covering facility construction, collaborative research, workforce training, and program development. It also outlines a competitive application process, specifying eligibility criteria (public-private partnerships, institutions of higher education, or consortia) and selection criteria, including applicant's potential, past performance, leveraging other initiatives, location, operational timeline, and co-investment.
Requires the Center of Excellence to establish intellectual property guidelines for research conducted within or in collaboration with it, in consultation with similar existing institutions like Manufacturing USA institutes, prior to commencing operations.
Section 3, new Section 36(d) of the NIST Act
Why it matters:This is standard legislative practice for establishing operational frameworks for new centers, ensuring that IP issues are addressed proactively and transparently.
Case for: Supporters argue that clear IP guidelines are essential to foster collaboration, encourage innovation, and ensure that the benefits of publicly funded research are appropriately managed and disseminated, while also protecting the interests of participating private entities.
Case against: Critics might argue that the specific details of IP management could significantly impact the willingness of private companies to participate, or that overly restrictive or permissive policies could hinder either innovation or public benefit.
Estimated impact: Significant impact on how research outcomes are commercialized and who benefits economically from the Center's innovations.